Palmitic Acid

Palmitic Acid

SCHEMBL1963468

CCCCCCCCCCCCCCCC(=O)O.CCCCCCCCCCCCCCCCC1(C(=O)O)CCCN1O

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.47
PPARG P37231 7/20 0.47
PPARD Q03181 7/20 0.47
PPARA Q07869 7/20 0.47
HDAC11 Q96DB2 5/20 0.47
TSHR P16473 4/20 0.47
PTPN1 P18031 3/20 0.47
FABP4 P15090 3/20 0.47
ALDH1A1 P00352 2/20 0.47
TLR2 O60603 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
KMT2A Q03164 2/20 0.47
ALOX15 P16050 2/20 0.47
HSD17B10 Q99714 2/20 0.47
SLC22A6 Q4U2R8 1/20 0.47
SLC22A8 Q8TCC7 1/20 0.47
MEN1 O00255 1/20 0.47
ESR1 P03372 1/20 0.47
PDE4A P27815 1/20 0.47
PDE3A Q14432 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Palmitic Acid SCHEMBL28077918 1.00 GPR84 (0.47) GPR84PPARGPPARDPPARAHDAC11
Palmitic Acid SCHEMBL28496754 1.00 GPR84 (0.47) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL27714853 0.93 L3MBTL1 (0.35) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL1248113 0.93 L3MBTL1 (0.35) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL28087493 0.91 L3MBTL1 (0.36) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL15955680 0.87 L3MBTL1 (0.33) TDP1KMT2AMEN1
Dioxane SCHEMBL28234971 0.84 HTT (0.36) TSHRTDP1KMT2AMEN1LMNA
SCHEMBL28234972 0.83 L3MBTL1 (0.31) TDP1KMT2AMEN1
Palmitic Acid SCHEMBL15659528 0.79 GPR84 (0.49) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL3382769 0.78 CPB2 (0.35) GPR84PPARGPPARDPPARAHDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8337870-B2 Low toxicity topical active agent delivery system YOUNG PHARMACEUTICALS, INC. (US) 2012-12-25 US claimed
CN-111973507-A External-use skin ointment and preparation method thereof 杨军 2020-11-24 CN disclosed
US-20180161435-A1 Low Toxicity Topical Active Agent Delivery System KULESZA JOHN E (US) 2018-06-14 US disclosed
EP-2512458-B1 LOW TOXICITY TOPICAL ACTIVE AGENT DELIVERY SYSTEM KULESZA JOHN E (US) 2016-05-18 EP disclosed
US-20150320867-A1 TOPICAL FORMULATIONS AND METHODS FOR THE USE THEREOF COTY INC. (US) 2015-11-12 US disclosed
WO-2014116653-A1 TOPICAL FORMULATIONS AND METHODS FOR THE USE THEREOF COTY INC. (US) 2014-07-31 WO disclosed
WO-2014066225-A1 LOW TOXICITY TOPICAL ACTIVE AGENT DELIVERY SYSTEM KULESZA JOHN E (US) 2014-05-01 WO disclosed
US-20130310355-A1 LOW TOXICITY TOPICAL ACTIVE AGENT DELIVERY SYSTEM YOUNG PHARMACEUTICALS INC (US) 2013-11-21 US disclosed
US-20130096203-A1 LOW TOXICITY TOPICAL ACTIVE AGENT DELIVERY SYSTEM YOUNG PHARMACEUTICALS, INC. (US) 2013-04-18 US disclosed
US-8337870-B2 Low toxicity topical active agent delivery system YOUNG PHARMACEUTICALS, INC. (US) 2012-12-25 US disclosed
EP-2512458-A1 LOW TOXICITY TOPICAL ACTIVE AGENT DELIVERY SYSTEM Kulesza, John E. (US) 2012-10-24 EP disclosed
WO-2011081672-A1 LOW TOXICITY TOPICAL ACTIVE AGENT DELIVERY SYSTEM KULESZA JOHN E (US) 2011-07-07 WO disclosed
US-20110142769-A1 LOW TOXICITY TOPICAL ACTIVE AGENT DELIVERY SYSTEM KULESZA JOHN E 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150320867-A1 TOPICAL FORMULATIONS AND METHODS FOR THE USE THEREOF CUTA, TSLP, MMP8 GPR84 1726/4885PPARG 679/4885PPARD 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.